Table 2.

Representative animal studies using FUS and therapeutics across the BBB/BBTB.

Therapeutic Agent	Animal Model	Outcome	References
Liposomal doxorubicin	Rat 9 L gliosarcoma	Increased median survival time (p = 0.0007)	Treat et al. [85]
IL4-liposomal doxorubicin	Human GBM 8401	Improved median survival time (p = 0.0001)	Yang et al. [86]
1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)	Rat C6 glioma	Improved median survival time (p = 0.015)	Liu et al. [87]
Temozolomide	Rat 9L gliosarcoma	Mean survival time increased 37.7%	Wei et al. [89]
Temozolomide	Human U87 glioma	Prolonged mean survival time (p < 0.05)	Liu et al. [90]
Carboplatin	Rat F98 glioma	Increase median survival time (p < 0.01)	McDannold et al. [91]
Paclitaxel	Patient-derived glioma xenografts (PDX)	In MES83 model: extended median survival (p = 0.0006); in GBM12 model, increased survival (p < 0.001)	Zhang et al. [92]